| Outcome Measures: |
Primary: CD34+ Endothelial Progenitor Cells Number, We will use patient's peripheral blood derived CD34+ cells looking at number of CD34+ Endothelial Progenitor Cell as % of the total Mononuclear cell population. Post saxagliptin will be compared to pre saxagliptin measurement, Up to 12 weeks post saxagliptin|CD 34+ Cell Function, function of EPC cell as migration of CD34+ cells in response to SDF-1a ( 100 ng/mL). Results are expressed in fluorescence ratio between cells exposed to the chemotactic factor and cells exposed to chemo attractant-free media ( control) followed by lysis in presence of CyQuant GR dye., Up to 12 weeks post saxagliptin Up to 12 weeks post saxagliptin: Visit 1 at Baseline, Visit 2 at 6 weeks, and Visit 3 at 12 weeks | Secondary: Serum Endothelial Inflammatory Marker hsCRP, Baseline 6 and 12 weeks post saxagliptin|Fasting Lipid Profile LDL/HDL, ratio of LDL over HDL, Baseline, 6 and 12 weeks post saxagliptin|Glycemic Control, measuring HbA1c levels, Baseline, 6 and 12 weeks post saxagliptin|Adiposity, measured using a Tanita Body Composition Fat Analyzer scale, measured as percentage body fat, Baseline, 6 and 12 weeks post saxagliptin|Arterial Stiffness, Arterial stiffness assessed using Vascular Flow and wave measurement equipment, SphygmoCor CP system from ATCOR. Reported as Augmentation Index adjusted for a heart rate of 75. Augmentation index (AIx) is a measure of systemic arterial stiffness derived from the ascending aortic pressure waveform. Lower the value, better correlated outcome as positive augmentation represents stiffer artery., Baseline, 6 and 12 weeks post saxagliptin
|
